From MarketBeat:



Analysts at LADENBURG THALM/SH SH began coverage on shares of PMV Pharmaceuticals (NASDAQ:PMVP) with a “buy” rating and a $7.00 price target. This suggests a potential upside of 127.27% from the current price. HC Wainwright also set a “buy” rating but dropped their price target on PMVP from $29.00 to $5.00. The stock opened at $3.08 on Wednesday with a market capitalization of $157.57 million. The company last reported quarterly earnings and beat consensus estimates.

Additionally, insider activity saw major shareholder Orbimed Advisors Llc selling 87,786 shares of stock. Institutional trading of PMVP showed a number of investors adding or reducing their stakes in the company. PMVP has seen investments from Royal Bank of Canada, Quantbot Technologies LP, US Bancorp DE, Simplex Trading LLC, and State Board of Administration of Florida Retirement System. PMVP’s lead product candidate is PC14586, a small molecule that corrects mutant p53 protein.

Despite the “Buy” rating from analysts, top-rated analysts have identified five other stocks that they believe are better buys, suggesting that PMVP may not be the best investment option at present.



Read more: LADENBURG THALM/SH SH Initiates Coverage on PMV Pharmaceuticals (NASDAQ:PMVP)